Per rectal diclofenac tablet (suppository) and inraveous fluid (Ringer lactate) are already proven for decreasing adverse effect (pancreatitis) after an endoscopic procedure (ERCP). We will be combining both methods to see whether they can further decrease the adverse effect of ERCP.
Not yet recruiting
- Conditions
- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere,
- Registration Number
- CTRI/2020/09/027536
- Lead Sponsor
- Department of Gastroenterology
- Brief Summary
Patientsundergoing endoscopic retrograde cholangiopancreatography (ERCP) has arisk of developing pancreatitis post ERCP. Rectal diclofenac and ringer lactatesolution infusion are proven prophylaxis to prevent post ERCP pancreatitis. Weare comparing the combination of these two prophylaxis modalities to either oneof them. Our hypothesis is that combined prophylaxis would be better thaneither one of them.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- All
- Target Recruitment
- 171
Inclusion Criteria
Patients having high risk factors for post ERCP pancreatitis.
Exclusion Criteria
Pregnancy, Patient with contraindication for diclofenac and ringer lactate, Patient with active acute pancreatitis, Patient not giving consent.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decrease in incidence of post ERCP pancreatitis in combination prophylaxis group,in comparison to prophylaxis by individual therapy(rectal diclofenac OR Ringers lactate) After 24 hours of procedure diagnosis of pancreatitis would be looked for.
- Secondary Outcome Measures
Name Time Method Decrease in hospital stay 24 hours after ERCP
Trial Locations
- Locations (1)
Department of Gastroenterology
🇮🇳Mumbai, MAHARASHTRA, India
Department of Gastroenterology🇮🇳Mumbai, MAHARASHTRA, IndiaRavi ThanagePrincipal investigator9028785843ravi.thanage@gmail.com